The rapid evolution of genetic engineering, particularly the rise of CRISPR-Cas9, has brought humanity to a pivotal crossroads: should we use this technology not just to cure disease—but to design future generations?
Originally developed as a tool for correcting mutations and treating hereditary conditions, gene editing is now advancing into uncharted ethical territory. Scientists can potentially alter physical traits, enhance intelligence, or increase resistance to disease—even before a child is born.
Supporters argue that such interventions could eliminate devastating genetic disorders, reduce healthcare burdens, and offer children a better quality of life. Critics, however, warn of “designer babies,” inequality, and unknown long-term consequences. As history has taught us, science without ethical boundaries can lead to harmful misuse—especially when market forces, national interests, or elitist agendas come into play.
The core ethical dilemma lies in autonomy: can an unborn child consent to being genetically edited? Who decides what constitutes a "desirable" trait? And what happens when such editing becomes a commodity accessible only to the wealthy?
In 2018, the world was shaken when a Chinese scientist claimed to have created the first gene-edited babies. The backlash was swift—and global. As a result, many countries have since banned or heavily regulated germline editing (changes passed on to future generations).
We now face a critical question: do we have the right to design life itself?
BONA invites you to reflect on the balance between innovation and integrity. In the pursuit of progress, let us not forget the value of diversity, consent, and shared humanity.